The Latest

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    At least four neuroscience-focused biotechs have raised venture fundings since late October, matching the total number of rounds raised by brain drug developers over the previous six months, according to BioPharma Dive data.

    Updated 12 hours ago
  • The interior of a specialized life sciences cleanroom facility designed for cultivating and manufacturing sustainable food products.
    Image attribution tooltip
    Permission granted by DPR Construction/Emily Hagopian
    Image attribution tooltip
    Sponsored by DPR Construction

    Making the ‘impossible’ executable in life sciences construction

    Why early technical expertise matters when complex life sciences projects challenge convention.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam’s base editing therapy for sickle cell hits goal in pivotal trial

    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

  • A person points to the start of a successful business on a blue stock market graph.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    PepGen soars on promising early data for muscular dystrophy drug

    While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics. 

  • Vivek Ramaswamy embraces a woman onstage at an Ohio Republican election-night event in Columbus, Ohio.
    Image attribution tooltip
    Jon Cherry via Getty Images
    Image attribution tooltip
    Trump administration

    Ramaswamy’s biotech baggage haunted his political run

    A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Brain drug revival

    London biotech Oyster harvests $60M for tau-targeting brain drugs

    Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Rezera and Windward Bio are set to go public Wednesday and Thursday, respectively, in a pair of offerings that could each pull in more than $200 million.

    Updated Nov. 11, 2026
  • Bayer
    Image attribution tooltip
    Permission granted by Bayer
    Image attribution tooltip

    Bayer wins FDA nod for a new kind of blood thinner

    Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention. 

    FDA
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

    The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”

    Updated Nov. 9, 2026
  • A drop of liquid is held via a pipette above a row of vials.
    Image attribution tooltip
    deliormanli via Getty Images
    Image attribution tooltip

    Argenx to buy peptide platform in potentially billion-dollar deal

    For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.

  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: 3 drug launches Wall Street is watching

    The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.

  • A 3D illustration of a human liver.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vir hepatitis D drug succeeds in first pivotal study

    A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Argenx and CorMedix both struck deals on Monday, with the former acquiring peptide drugmaker Unnatural Products and the latter scooping up Heron Therapeutics, which sells medicines for postoperative pain and nausea.

    Updated Nov. 9, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.

  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    At ASH, drugmakers to showcase early data for three-pronged cancer therapies

    J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.

  • An image of people cheering and holding up American flags
    Image attribution tooltip
    Jim Vondruska / Stringer via Getty Images
    Image attribution tooltip
    Trump administration

    Biopharma likely to climb higher after ‘blue wave,’ analysts say

    Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.

  • A photo of the packaging for the pancreatic cancer drug Rasonque
    Image attribution tooltip
    Retrieved from Revolution Medicines.
    Image attribution tooltip

    Revolution’s Rasonque off to best cancer drug launch ‘in history’

    Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.

  • An illustration of a bispecific antibody (yellow and orange) binding to two different membrane proteins (purple and blue).
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    T-Therapeutics reloads with a $133M megaround for bispecifics

    The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Evommune could pay up to $1.13 billion in a deal for rights to a molecular glue drug, while Caldera Therapeutics snapped up a bispecific antibody aimed at two popular immune disease targets.

    Updated Nov. 6, 2026
  • A concrete sign outside of a building reads "Department of Health & Human Services" wrapped around the HHS logo.
    Image attribution tooltip
    Kayla Bartkowski via Getty Images
    Image attribution tooltip

    Medicare will cut billions from 340B, expand site-neutral payments in 2027

    Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some payments between care sites. Hospitals railed against the rule.

  • Two scientists work in a laboratory at Alethio Therapeutics' headquarters.
    Image attribution tooltip
    Permission granted by Alethio Therapeutics
    Image attribution tooltip
    Startup launches

    Alethio raises $90M to target rare blood cancers

    The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.

  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi stops development of Nurix-partnered immune drug

    The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6. 

  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts

    The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.

  • Vertex
    Image attribution tooltip
    Permission granted by Vertex
    Image attribution tooltip

    Vertex, ahead of FDA decision, calms fears surrounding kidney drug

    On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.